Refine
Has Fulltext
- yes (123)
Is part of the Bibliography
- yes (123)
Year of publication
Document Type
- Journal article (112)
- Conference Proceeding (4)
- Doctoral Thesis (4)
- Review (2)
- Book article / Book chapter (1)
Keywords
- Toxikologie (123) (remove)
Institute
Terahertz electromagnetic fields are non-ionizing electromagnetic fields in the frequency range from 0.1 to 10 THz. Potential applications of these electromagnetic fields include the whole body scanners, which currently apply millimeter waves just below the terahertz range, but future scanners will use higher frequencies in the terahertz range. These and other applications will bring along human exposure to these fields. Up to now, only a limited number of investigations on biological effects of terahertz electromagnetic fields have been performed. Therefore, research is strongly needed to enable reliable risk assessment. Cells were exposed for 2 h, 8 h, and 24 h with different power intensities ranging from 0.04 mW/cm2 to 2 mW/cm2, representing levels below, at, and above current safety limits. Genomic damage on the chromosomal level was measured as micronucleus formation. DNA strand breaks and alkali-labile sites were quantified with the comet assay. No DNA strand breaks or alkali-labile sites were observed as a consequence of exposure to terahertz electromagnetic fields in the comet assay. The fields did not cause chromosomal damage in the form of micronucleus induction.
Streptococcus pneumoniae is a common pathogen that causes various infections, such as sepsis and meningitis. A major pathogenic factor of S. pneumoniae is the cholesterol-dependent cytolysin, pneumolysin. It produces cell lysis at high concentrations and apoptosis at lower concentrations. We have shown that sublytic amounts of pneumolysin induce small GTPase-dependent actin cytoskeleton reorganization and microtubule stabilization in human neuroblastoma cells that are manifested by cell retraction and changes in cell shape. In this study, we utilized a live imaging approach to analyze the role of pneumolysin’s pore-forming capacity in the actin-dependent cell shape changes in primary astrocytes. After the initial challenge with the wild-type toxin, a permeabilized cell population was rapidly established within 20–40 minutes. After the initial rapid permeabilization, the size of the permeabilized population remained unchanged and reached a plateau. Thus, we analyzed the non-permeabilized (non-lytic) population, which demonstrated retraction and shape changes that were inhibited by actin depolymerization. Despite the non-lytic nature of pneumolysin treatment, the toxin’s lytic capacity remained critical for the initiation of cell shape changes. The non-lytic pneumolysin mutants W433F-pneumolysin and delta6-pneumolysin, which bind the cell membrane with affinities similar to that of the wild-type toxin, were not able to induce shape changes. The initiation of cell shape changes and cell retraction by the wild-type toxin were independent of calcium and sodium influx and membrane depolarization, which are known to occur following cellular challenge and suggested to result from the ion channel-like properties of the pneumolysin pores. Excluding the major pore-related phenomena as the initiation mechanism of cell shape changes, the existence of a more complex relationship between the pore-forming capacity of pneumolysin and the actin cytoskeleton reorganization is suggested.
Evaluation of 1H-NMR and GC/MS-based metabonomics for the assessment of liver and kidney toxicity
(2009)
For the assessment of metabonomics techniques for the early, non-invasive detection of toxicity, the nephrotoxins gentamicin (s.c. administration of 0, 60 and 120 mg/kg bw 2x daily for 8 days), ochratoxin A (p.o. administration of 0, 21, 70 and 210 µg/kg bw 5 days/week for 90 days) and aristolochic acid (p.o. administration of 0, 0.1, 1.0 and 10 mg/kg bw for 12 days) were administered to rats and urine samples were analyzed with 1H-NMR and GC/MS. Urine samples from the InnoMed PredTox project were analyzed as well, thereby focusing on 1H-NMR analysis and bile duct necrosis as histopathological endpoint. 1H-NMR analysis used water supression with the following protocol: 1 M phosphate buffer, D2O as shift lock reagent, D4-trimethylsilylpropionic acid as chemical shift reference, noesygppr1d pulse sequence (Bruker). For multivariate data analysis, spectral intensity was binned into 0.04 ppm wide bins. GC/MS analysis of urine was carried out after protein precipitation with methanol, drying, derivatization with methoxyamine hydrochloride in pyridine and with methyl(trimethylsilyl)trifluoroacetamide on a DB5-MS column using EI ionization. The chromatograms were prepared for multivariate data analysis using the R-program based peak picking and alignment software XCMS version 2.4.0. Principal component analysis (PCA) to detect and visualize time-point and dose-dependent differences between treated animals and controls and orthogonal projection to latent structures discriminant analysis (OPLS-DA) for identification of potential molecular markers of toxicity was carried out using SIMCA P+ 11.5 1H-NMR-based markers were identified and quantified with the Chenomx NMR Suite, GC/MS based markers were identified using the NIST Mass Spectral Database and by co-elution with authentic reference standards. PCA of urinary metabolite profiles was able to differentiate treated animals from controls at the same time as histopathology. An advantage over classical clinical chemistry parameters regarding sensitivity could be observed in some cases. Metabonomic analysis with GC/MS and 1H-NMR revealed alterations in the urinary profile of treated animals 1 day after start of treatment with gentamicin, correlating with changes in clinical chemistry parameters and histopathology. Decreased urinary excretion of citrate, 2-oxoglutarate, hippurate, trigonelline and 3-indoxylsulfate increased excretion of 5-oxoproline, lactate, alanine and glucose were observed. Ochratoxin A treatment caused decreased excretion of citrate, 2-oxoglutarate and hippurate and and increased excretion of glucose, myo-inositol, N,N-dimethylglycine, glycine, alanine and lactate as early as 2 weeks after start of treatment with 210µg OTA/kg bw, correlating with changes in clinical chemistry parameters and histopathology. Integration of histopathology scores increased confidence in the molecular markers discovered. Aristolochic acid treatment resulted in decreased urinary excretion of citrate, 2-oxoglutarate, hippurate and creatinine as well as increased excretion of 5-oxoproline, N,N-dimethylglycine, pseudouridine and uric acid. No alterations in clinical chemistry parameters or histopathology were noted.Decreased excretion of hippurate indicates alterations in the gut microflora, an effect that is expected as pharmacological action of the aminoglycoside antibiotic gentamicin and that can also be explained by the p.o. administration of xenobiotica. Decreased Krebs cycle intermediates (citrate and 2-oxoglutarate) and increased lactate is associated with altered energy metabolism. Increased pseudouridine excretion is associated with cell proliferation and was observed with aristolochic acid and ochratoxin A, for which proliferative processes were observed with histopathology. 5-oxoproline and N,N-dimethylglycine can be associated with oxidative stress. Glucose, a marker of renal damage in clinical chemistry, was observed for all three nephrotoxins studied. Single study analysis with PCA of GC/MS chromatograms and 1H-NMR spectra of urine from 3 studies conducted within the InnoMed PredTox project showing bile duct necrosis revealed alterations in urinary profiles with the onset of changes in clinical chemistry and histopathology. Alterations were mainly decreased Krebs cycle intermediates and changes in the aromatic gut flora metabolites, an effect that may result as a secondary effect from altered bile flow. In conclusion, metabonomics techniques are able to detect toxic lesions at the same time as histopathology and clinical chemistry. The metabolites found to be altered are common to most toxicities and are not organ-specific. A mechanistic link to the observed toxicity has to be established in order to avoid confounders such as body weight loss, pharmacological effects etc. For pattern recognition purposes, large databases are necessary.
Gegenstand der vorliegenden Untersuchung ist das Leben und Werk des deutschen Pharmakologen und Toxikologen Wilhelm Neumann (11. Februar 1898 - 15. April 1965). Wesentliche Erkenntnisse hierzu konnten aus Aktenbeständen des Bundesarchivs der Bundesrepublik Deutschland in Berlin-Lichterfelde, Freiburg im Breisgau, und Koblenz, des Dekanatsarchiv der Medizinischen Fakultät der Bayerischen Julius-Maximilians-Universität Würzburg, des Archivs der „Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie“ in Mainz, des Scheringianums, dem Archiv der Schering AG in Berlin, des Staatsarchivs Würzburg und des Universitätsarchivs der Bayerischen Julius-Maximilians-Universität Würzburg gewonnen werden. Von 1919 bis 1923 studierte Wilhelm Neumann in Berlin Chemie und promovierte in der chemischen Abteilung des Preußischen Instituts für Infektionskrankheiten „Robert Koch“ zum Dr. phil. Im Jahr 1924 trat er eine Stelle als Privatassistent am Pharmakologischen Institut der Universität Würzburg unter der Leitung Ferdinand Flurys an. Parallel zu seiner Arbeit am Pharmakologischen Institut studierte er von 1929 bis 1934 an der Universität Würzburg Humanmedizin und promovierte zum Dr. med. 1937 folgte seine Habilitation und die Ernennung zum Dozenten. Weitere Stationen seiner wissenschaftlichen Laufbahn am Pharmakologischen Institut waren die Ernennungen zum planmäßigen Assistenten 1939, zum Konservator 1941 und zum außerplanmäßigen Professor 1942. Im Jahr 1937 nahm Wilhelm Neumann als Arzt der Reserve seine militärische Karriere im Sanitätsdienst der Wehrmacht auf. Während des Zweiten Weltkrieges war er als „beratender Arzt“ und als Wissenschaftler für die Wehrmacht tätig. Neumanns politischer Werdegang begann im Juli 1933 mit seinem Beitritt zur Veteranenorganisation Stahlhelm. Im Februar 1934 wurde er Mitglied der SA, und ab dem 1. Mai 1937 gehörte er der NSDAP an. Nach Ende des Zweiten Weltkrieges wurde Neumann im Zuge des Entnazifizierungsprozesses 1946 aus dem Staatsdienst entlassen. Das 1947 ergangene Spruchkammerurteil reihte ihn in die Gruppe der „Mitläufer“ ein. Infolgedessen konnte er 1948 wieder von der Universität Würzburg eingestellt werden. Im Jahr 1949 wurde er dort zum ordentlichen Professor für Pharmakologie und Toxikologie berufen. Von 1954 bis 1955 übte er das Amt des Dekans der Medizinischen Fakultät der Universität Würzburg aus. Am Pharmakologischen Institut der Universität Würzburg untersuchte Neumann zunächst die Chemie und Pharmakologie der herzwirksamen Glykoside. Ihm gelang auf diesem Gebiet die Reindarstellung eines neuen Wirkstoffs, der 1935 von der Firma Schering im Herzinsuffizienztherapeutikum Folinerin auf den Markt gebracht wurde. Auf toxikologischem Gebiet arbeitete er von 1925 bis 1945 mit Ferdinand Flury an gewerbetoxikologischen Projekten und in der chemischen Kampfstoff-Forschung. Als ordentlicher Professor widmete sich Wilhelm Neumann dann neben eigenen toxikologischen Arbeiten der Förderung der Toxikologie als Fachrichtung. Zu Beginn der 1950er Jahre befasste er sich mit tierischen Giften und erforschte die Toxikologie der Reizgase und der Luftverschmutzung. Von 1955 bis 1965 war Wilhelm Neumann Vorsitzender der DFG-Kommission zur Prüfung gesundheitsschädlicher Arbeitsstoffe.
Azoles are important chemicals used as antifungal agents in agriculture and human medicine, but also as cytostatic drugs in tumour chemotherapy. Antifungal activities are based on inhibition of lanosterol-14α-demethylase (CYP51). CYP51 catalyses the oxidative removal of the methyl group # 32 of lanosterol to produce follicular fluid meiosis activating steroid (FF-MAS). For fungi the later resulting ergosterol is an essential compound of the cell membrane. Exposed fungi lack ergosterol, which leads to a collapse of the cell membrane. In mammals cholesterol, the downstream product of lanosterol-14α-demethylation necessary for the synthesis of bile acids, mineral corticoids, glucocorticoids and sex steroids, can be supplemented with food intake. However FF-MAS and the resulting T-MAS (testis meiosis activating steroids), the direct products of the CYP51 reaction, act as meiosis-activating steroids on ovaries and testes and are not supplemented with food intake. Inhibition of CYP51 in humans may therefore affect the endocrine system and is an unwanted side effect of azoles. Aromatase (CYP19) catalyses the demethylation of testosterone to estradiol and is inhibited by azoles. Reduction of estrogen levels by CYP19 inhibition is the working principle of cytostatic drugs used in breast cancer therapy but is considered an unwanted side effect for azoles used to treat fungal infections. A favourable fungicide or antifungal drug should be a strong inhibitor of fungal CYP51. In contrast human CYP51 and human CYP19 should not be inhibited by an azole fungicide or antifungal agent. The favourable cytostatic drug should show a high potency towards human CYP19. Neither human CYP51 nor fungal CYP51 should be inhibited by a cytostatic drug. The aim of this work was to assess: are fungicides and antifungal drugs strong inhibitors of fungal CYP51? In return do they not inhibit human CYP51 and human CYP19? Do cytostatic drugs strongly inhibit human CYP19? And in return do they not inhibit human CYP51 or fungal CYP51? Inhibitory potencies of 22 azole compounds used for the three purposes were tested in four inhibition assays: i) on commercially available human CYP19 utilising a fluorescent pseudo substrate dibenzylfluorescein (DBF) ii) on CYP19 utilising testosterone as substrate iii) on human CYP51 and iv) Candida albicans CYP51 utilising lanosterol as substrate. Product formation was measured by liquid chromatography – tandem mass spectrometry utilising photospray ionisation (APPI). A functional human CYP51 was available from BD Gentest Cooperation. A functional enzyme complex comprising of the Candida albicans lanosterol-14α-demethylase and the Candida tropicalis oxidoreductase was expressed in the baculovirus system. When comparing inhibitory potencies on CYP19, human CYP51 and Candida albicans CYP51 a number of agents show desirable patterns of inhibition e.g. the two cytostatic drugs, or two antifungal agents used in human medicine, fluconazole and itraconazole, and a wide variety of the fungicides, e.g. cyproconazole and hexaconazole. Undesirable patterns of inhibition were exhibited by a number of compounds, e.g. prochloraz, bifonazole, ketoconazole and miconazole. Seven compounds show a more complex picture of inhibitory potencies though. To get a picture of residue levels of azoles in food in a model case an LC-ESI-MS/MS method was developed for the determination of azole compounds in wine. All residues were below the maximum residue levels set by authorities. To classify the inhibitory potencies on the different enzyme systems IC50 values obtained were compared to exposure levels measured in farmers, maximum plasma concentrations in humans reported after exposure to antifungal drugs and to acceptable daily intake levels set by authorities. Based on the findings presented, the following conclusions can be drawn. The risk for agricultural workers set by exposure to azole fungicides with respect to human CYP51 and CYP19 can be regarded as negligible when safety measures are adhered to. As a matter of principle however, the usage of bifonazole, miconazole and ketoconazole has to be viewed with caution in respect to the high level of inhibition of human CYP51 and/or CYP19. Under the assumption that the acceptable daily intake amounts set by authorities for azole compounds are not exceeded the residues do not pose a threat to consumer safety judged by our findings. Inhibition of CYP19 with the consequence of a reduction of estradiol levels has to be regarded as a possible disrupting effect of the hormone balance. The relevance of FF-MAS and T-MAS in the endocrine system however still has to be evaluated completely bringing with it the question of how much importance has to be attached to the inhibition of human CYP51.
Bei Daidzein und Bisphenol A handelt es sich um zwei Vertreter einer Klasse von Stoffen, die als „Umwelthormone“ (engl. endocrine disrupter) bezeichnet werden. Aus der Gruppe der Phytoöstrogene wurde Daidzein als wichtiger Vertreter, der in hohen Konzentrationen in vielen Nutzpflanzen und Nahrungsmitteln vorkommt, ausgewählt. Sojaprodukte, die den größten Beitrag einer menschlichen Exposition gegen Daidzein liefern, werden in zunehmendem Maße auch in westlichen Ländern konsumiert. Bisphenol A wurde als Vertreter der Xenoöstrogene gewählt, da es - was Weltjahresproduktion und Verwendung angeht - die wohl wichtigste Substanz dieser Gruppe darstellt. Im ersten Teil der Arbeit wurde die Biotransformation und Toxikokinetik der beiden Verbindungen nach oraler Gabe in der Ratte aufgeklärt. Dabei konnte gezeigt werden, daß die orale Bioverfügbarkeit beider Substanzen in der Ratte sehr gering war. Maximal zehn Prozent der jeweils applizierten Dosis konnten im Urin der Tiere wiedergefunden werden. Als Hauptmetabolit wurden sowohl von Daidzein als auch von Bisphenol A das jeweilige Glucuronid-Konjugat gebildet. Bei Daidzein überwog in der männlichen Ratte zusätzlich das Sulfat-Konjugat. Der Anteil an freier, d.h. unkonjugierter Verbindung betrug im Urin der Tiere zwischen 1 und 3 Prozent der Dosis. Außer den Phase II-Konjugaten, die aufgrund ihrer mangelnden östrogenen Wirksamkeit zu einer Detoxifizierung der beiden Verbindungen führte, konnten nach Gabe von Bisphenol A in der Ratte keine weiteren Metabolite identifiziert werden. Nach Exposition mit Daidzein konnten in den Faeces der Tiere in geringem Umfang die beiden reduktiven Metabolite Equol und O-DMA gefunden werden. Diese wurden wahrscheinlich im Magen-Darm-Trakt durch die Bakterien der Darmflora gebildet. Sowohl Daidzein als auch Bisphenol A wurden bei der Ratte nur unvollständig aus dem Magen-Darm-Trakt resorbiert; der Großteil der gegebenen Dosis wurde als unveränderte Substanz in den Faeces wiedergefunden. Bei Bisphenol A wurde die Ausscheidung zudem durch einen ausgeprägten enterohepatischen Kreislauf verzögert. Im zweiten Teil der Arbeit wurden zunächst empfindliche GC/MS- und HPLC-Methoden zur Quantifizierung der Verbindungen in humanen Plasma- und Urinproben entwickelt. Danach wurden freiwillige Probanden oral mit jeweils 5 mg Daidzein bzw. d16-Bisphenol A exponiert, um Daten zur Biotransformation und Toxikokinetik der beiden Substanzen im Mensch zu erhalten. Wegen des deutlich meßbaren Hintergrundes an Bisphenol A, das in allen Kontrollproben nachweisbar war, wurde für die Humanstudie die deuterierte Verbindung gegeben, für die kein störender Hintergrund meßbar war. Die Bioverfügbarkeit der Gesamt-Substanz (freie Verbindung + Konjugate) im Menschen war in beiden Fällen deutlich höher als in der Ratte. Von Daidzein wurden 40 Prozent (Ratte 10 Prozent), von Bisphenol A > 95 Prozent (Ratte 13 Prozent) der applizierten Dosis im Urin der Probanden wiedergefunden. Dabei zeigte sich ein sehr effizienter Phase II-Metabolismus; weniger als 1 Prozent der Glucuronid-Konjugatkonzentrationen wurden als unveränderte Substanz gefunden. Das Glucuronid stellte in beiden Fällen den einzigen nachweisbaren Metaboliten dar. Die Elimination von Daidzein und Bisphenol A verlief in den beiden Studien sehr schnell nach einer Kinetik erster Ordnung. Im Gegensatz zu der Ratte konnten auch bei Bisphenol A keine Auffälligkeiten in den Ausscheidungskurven beobachtet werden, Hinweise auf einen enterohepatischen Kreislauf im Menschen wurden nicht gefunden. Im Falle von Bisphenol A wurde fast die komplette applizierte Dosis (> 95 Prozent) in Form des Glucuronides im Urin wiedergefunden. Anhand der erhobenen Daten wurde anschließend eine Beurteilung des Risikos für den Menschen abgegeben.
The rate limiting step in 5-fluorouracil catabolism is catalyzed by the enzyme dihydropyrimidine dehydrogenase. Since degradation of 5-fluorouracil decreases its efficacy in chemotherapy, the inhibition of its catabolism is a promising tool. We investigated the formation of micronuclei in vitro in mouse L5178Y cells. 5-fluorouracil induced an increase in micronucleus frequency, which could significantly be enhanced by the concurrent application of 2,6-dihydroxypyridine, an inhibitor of dihydropyrimidine dehydrogenase. The 5-fluorouracil concentration necessary to reach maximal genotoxic effects could be reduced to half in the presence of inhibitor. 2,6-Dihydroxypyridine alone and the naturally occuring enzyme substrate uracil did not induce micronucleus formation. Combined application of the chemotherapeutic agent 5-fluorouracil and an inhibitor of its could reduce side-effects by lowering the effective dose of the active drug. With this study we provide further support for the usefulness of this concept.
This study was designed to investigate a previously unidentified potential mechanism for mutation induction as well as to clarify a biological comequence of micronucleus formation. We compared the induction of micronuclei with mutation inductioo as measured by trißuorothymidine (TFI') resistance in mouse L5178Y cells using four aneugens: colcemid, diethylstilbestrol, griseofulvin and vioblastine. AU four compounds induced micronuclei which appeared in the first cell cycle after treatment. More than 85% of the micronuclei induced by each compound stained positive for the presence of kinetochores implying that the micronuclei contained wbole cbromosomes. However, these same compounds were unable to induce TFf resistance under tbree different treatment regimes. We concluded that tbese compounds, under conditions where tbey induce primarily kinetochore positive micronuclel, were not able to induce mutations. Thus, the induction of micronuclei containing wbole chromosomes barborlog a select.able gene is not an early event leadlog to mutations in these cells.